---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-036402"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:26:20.696149+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q1 net loss $6.5M; cash $51M; advances DN-TNF and INKmune trials

## Summary
- Net loss $6.5M vs $6.9M YoY; R&D $4.1M, G&A $2.3M.
- Cash and equivalents $51.0M at March 31, 2023; 17.9M shares outstanding.
- FDA provides clear pathway to lift clinical hold on AD Phase 2 by year-end.
- IND filed for INKmune in mCRPC; Phase 1 in MDS/AML enrolling at three sites.
- Top-line XPro Alzheimer's results expected 2H 2024; NIH-funded depression trial pending FDA.

## SEC filing metadata
- accession: 0001213900-23-036402
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/0001213900-23-036402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/ea177977-8k_inmunebio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-036402
- JSON: https://secwatch.observer/filing/0001213900-23-036402.json
- Plain text: https://secwatch.observer/filing/0001213900-23-036402.txt

## Key facts
- Earnings Releases
  Inmune Bio, Inc. reported the quarter ended March 31, 2023 results: net income approximately $6.5 million.
  - Period: the quarter ended March 31, 2023
  - Net income: approximately $6.5 million
  - Result: reported results
  source text: Net loss attributable to common stockholders for the quarter ended March 31, 2023 was approximately $6.5 million, compared to approximately $6.9 million during the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/0001213900-23-036402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.